Ponzoni, Maurilio
https://orcid.org/0000-0002-0055-325X
Mayo Clinic
Vita-Salute San Raffaele University
Citations 22
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program
Xu‐Monette, Zijun Y. , Møller, Michael , Tzankov, Alexandar , Montes‐Moreno, Santiago , Hu, Wenwei , Manyam, Ganiraju C. , Kristensen, Louise , Fan, Lei , Visco, Carlo , Dybkær, Karen , Chiu, April , Tam, Wayne , Zu, Youli , Richards, Kristy L. , Choi, William W.L., Krieken, J. Han van , Huang, Qin , Huh, Jooryung , Ferreri, Andrés J.M. , Zhao, Xiaoying , Bueso‐Ramos, Carlos E. , Wang, Sa A. , Winter, Jane N. , Piris, Miguel Á. , Medeiros, L. Jeffrey , Young, Ken H. , Bhagat, Govind , Hsi, Eric D. , Ai, Weiyun Z. , Ponzoni, Maurilio , Wu, Lin , Go, Ronald S. , Li, Yong , Møller, Michael Boe , Winter, Jane N , Tzankov, Alexandar , Dybkaer, Karen , van Krieken, J Han , Young, Ken H , Piris, Miguel , Medeiros, L Jeffrey , Zu, Youli , Montes-Moreno, Santiago , Xu-Monette, Zijun Y
Blood | August 28, 2013 | Volume: 122 | Issue: 15 | Pages: 2630-2640
Key PointsPhenotypic and genotypic profiling of MDM2 in DLBCL. MDM2 as a negative regulator of p53 tumor suppressor function.
Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group
Shenkier, Tamara , Blay, Jean‐Yves , Poortmans, Philip , Thiel, Eckhard, Jahnke, Kristoph, Abrey, Lauren E. , Neuwelt, Edward A. , Tsang, Richard , Batchelor, Tracy T. , Ferreri, Andrés J.M. , O’Brien, Peter, Rubenstein, James L. , O’Neill, Brian Patrick , Harris, Nancy L. , Ponzoni, Maurilio , Connors, Joseph M. , Blay, Jean-Yves
Journal of Clinical Oncology | March 30, 2005 | Volume: 23 | Issue: 10 | Pages: 2233-2239
Purpose To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL). Patients and Methods A retrospective series of patients with TPCNSL was compiled from twelve cancer centers in seven countries. Results We identified 45 patients with a median age of 60 years (range, 3 to 84 years). Twenty (44%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Twenty-six (58%) had involvement of a cerebral hemisphere and sixteen (36%) had lesions of deeper sites in the brain. Serum lactate dehydrogenase was elevated in 7 (32%) of 22 patients, and CSF protein was elevated in 19 of 24 patients (79%) with available data. The median disease-specific survival (DSS) was 25 months (95% CI, 11 to 38 months). The 2- and 5-year DSS were 51% (95% CI, 35% to 66%) and 17% (95% CI, 6% to 34%), respectively. Univariate and multivariate analyses were conducted for age (≤ 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no). Only PS and MTX use were significantly associated with better outcome with hazard ratios of 0.2 (95% CI, 0.1 to 0.4) and 0.4 (95% CI, 0.2 to 0.8), respectively. Conclusion This is the largest series ever assembled of TPCNSL. The presentation and outcome appear similar to that of B cell PCNSL. PS 0 or 1 and administration of MTX are associated with better survival.